Abstract
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer death. However, the molecular mechanisms underlying CRC initiation, growth and metastasis are poorly understood. In this study, based on our previous work for comprehensively analyzing miRNA sequencing data, we examined a series of colorectal cancer microRNAs expression profiles data. Results show that all these CRC samples share the same four pathways including TGF-beta signaling pathway, which is important in colorectal carcinogenesis. Twenty-one microRNAs that evolved in the four overlapped pathways were then discovered. Further analysis selected miR-21 as an important regulator for CRC through TGF-beta pathways. This study develops methods for discovering tumor specific miRNA cluster as biomarker and for screening new cancer therapy targets based on miRNA sequencing.
Similar content being viewed by others
Introduction
Colorectal cancer (CRC) is a major cause of cancer-associated morbidity and mortality all over the world, with an estimated 1.4 million cases and 693,900 deaths occurring in 2012 according to the Global cancer statistics1,2. Invasion and metastasis are the major cause of this deathly cancer type. Although recent improvements in diagnostic techniques and clinical management have increased the early detection rate of CRC and decreased the mortality rate, more than one third of patients with CRC will ultimately develop into metastatic disease3. Until now, the pathogenesis of CRC is one of the most characterized carcinogenesis process, while new molecules that play a role in this process are still being discovered.
MicroRNAs (miRNAs) are small(approximately 20 ~ 22 nucleotides), noncoding RNAs that regulate gene expression by the inhibition of the translation and/or decreasing of the stability of their mRNA targets. It has been demonstrated that miRNAs play a significant role in tumorigenesis by down-regulating tumor suppressor genes or oncogenes4,5. MiRNAs were first discovered in 1993, after that approximately two thousand human miRNAs have been indentified, which have been proved to play important roles in various biological processes, including cell proliferation, cell cycle, apoptosis and differentiation6. An increasing number of miRNAs have been observed in various types of cancer and they were considered involving in modulating cancer cell behaviors7,8. Indeed, dysregulating of miRNAs were proved to be a key process in the pathogenesis of many cancers and may occur at any point, from initiation to metastasis stage9,10. Many studies have indicated that miRNAs were deregulated in various types of human malignancies such as colon cancer, breast cancer, lung cancer, pancreatic cancer, and chronic lymphocytic leukemia11,12. Circulating levels of miRNAs are also quite stable and reproducible in the body fluid of many cancer patient. Given the critical role of miRNAs in the development of tumors and their global regulation, it shows great promise to character or screen therapy targets for CRC13.
In complex disease analysis for gaining potential delicate biological insights, pathway-based approaches and sub-pathway-based approaches have become the first choice14,15,16. In this study, based on the mathematical model as presented in our previous work17, we comprehensively analyze four CRC samples aiming to try to characterize CRC and discover therapeutic targets based on miRNAs profile.
Materials and Methods
Data source
The miRNA microarrays that we used in this study were deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database with accession code GSE35602, which including four cases of CRC samples(GSM871528, GSM871531, GSM871533, GSM871535) and four cases of adjacent normal colorectal samples( GSM871539, GSM871541, GSM871543, GSM871545), as reported in18. In this study, total RNAs from epithelial tissue of cancer and normal samples were analyzed by miRNA microarray. Total RNAs were extracted from tissue using the miRNeasyMini Kit (Qiagen) according to the manufacturer’s protocol. Concentrations and purities of the total RNAs were assessed with a spectrophotometer and RNA integrity was verified using an Agilent 2100 Bioanalyzer (Agilent Technologies). Colon adenocarcinoma (COAD) miRNASeq data samples were obtained from The Cancer Genome Atlas (TCGA).
Methods
miRNA expression profiles data normalization
Measures of RNA abundance are important for many areas of biology and often obtained from high throughput RNA sequencing methods such as Illumina sequence data. So in this study, when receive miRNA expression profiles data, to remove technical biases inherent in the sequencing approach we first normalize the expression profiles data. Here we employ TPM(Transcripts per million)19 method to do this assignment. The TPM of a miRNA a is:
where A stands for the set of all miRNAs determined in that experiment and a is an index for a miRNA. So both in eq.(1) and (2) , the miRNAa represents transcripts number of miRNA a and miRNAtotal represents all miRNAs transcripts number in total in a sample.
A mathematical model to evaluate the comprehensive repression rate of specific mRNAs using total miRNA expression profiles
The method of evaluating the comprehensive repression rate of specific mRNAs using total miRNA expression profiles is as following17:
Where miRNAa and miRNAtotal are the same meaning as refer to in above eq.(1) and (2). RSi−α represents repression score of miRNAi on their target gene mRNAα, thereinto, i represents the indexes of miRNAs that share a specially target gene mRNAα. RSa−i represents repression score of specific miRNAa on its target gene miRNAi, here, the i represents the indexes of mRNAs that miRNAa will target on. Such repression score(RS) are extracted from miRanda20.
Statistical analysis
Z-tests were performed to investigate differences in the repression effect of target mRNAs by miRNAs. p0 was calculated using formula (4), which was used to investigate the null hypothesis.
Here, and indicates the repression of mRNAα in the control and test groups, whereas and indicates the accumulated repression effect on mRNAs respectively in control and test groups.
Then, the Z-test was performed according to the following formula:
Method workflow
step 1: Normalization for miRNA expression profile;
step 2: Compute the global repression effect of miRNA expression profile on their target genes;
step 3: Do differential analysis for target genes based on the repression score;
step 4: Do gene function enrichment analysis
Results and Discussions
Four CRC tissue samples and normal colorectal epithelial tissue datasets were used in this study. The miRNAs expression profiles data for four normal colorectal epithelial were averaged among four samples as control group. Then four samples of CRC were respectively analyzed versus the control group. Currently, the methods for analysing miRNAs profiles are mainly according to the following steps, step 1: differential analysis for miRNAs expression profiles and select the differentially expressed miRNAs; step 2: predicting the targets genes of selected miRNAs; step 3: mapping the selected target genes to whole pathways to find significant enrichment pathways that related to the submitted genes list. However, it has been reported that an individual miRNA may target several mRNAs with different suppression level. The comprehensive repression of a given miRNA pool should be carefully calculated. Indeed, context scores for ranking the predicted targets of each miRNA have been provided by previous studies21,22,23. To comprehensive analyze the global repression effect of miRNAs on their target genes, new method was bring forward in17.
Four groups of CRC and control samples were analyzed according to the method workflow mentioned in method section. Thereinto gene function enrichment analysis indicates four overlapped KEGG pathways(Type I diabetes mellitus, Allograft rejection, Graft-versus-host disease, TGF-beta signaling pathway)(see Fig. 1).
Then, we sort out all the significantly regulated mRNAs that participate in these pathways base on the reference provide by DAVID data base. Due to one miRNA can bind to many mRNAs and one mRNA can also be repressed by multiple miRNAs, hundreds of miRNAs will target to the significantly regulated mRNAs correlated to the overlapped pathways. Quite a few miRNAs (507) were overlapped between the four samples. The Venn Diagram of those mRNAs respectively in four samples of CRC versus control group were plotted in Fig. 2(a). Differential analysis was preformed after getting the repression effect of miRNAs on corresponding mRNAs in enriched pathways. Finally, significant differential miRNA-mRNA interactions were screened out. MiRNAs that occur in the significantly differential miRNA-mRNA interactions were thought to have relatively strong influence and significant differential repressed effect on their corresponding target gene. Results show that 27 miRNAs were overlapped between the four samples as described in Fig. 2(b).
To better understand the potential production mechanism of CRC, we narrow the searching space into four overlapped pathways. By doing differential analysis, results show that 21 miRNAs significantly regulate the mRNAs that correlated to four overlapped pathways as in Fig. 3(a). The mRNAs that were significantly regulated respectively in four samples were also obtained and statistical analysis was done as shown in Fig. 3(b).
For the 21 miRNAs screened out by above differential analysis, most of which also have been reported correlated to pathological mechanism of CRC in previous literatures list as in Table 1. To the best of our knowledge, 3 (3/21, 14.3%) miRNAs namely hsa-miR-16-2*, hsa-miR-30c-2* and hsa-miR-592 are without reports concerning with the CRC. Among the remaining 18 miRNAs , 16 (16/18, 88.9%) are respectively with an consistent change direction and 2 (2/18, 11.1%) with an inconsistent change direction among the published literatures(see Table 1).
As can be seen from Table 1, most of the 21 miRNAs were validated to be correlated to CRC, which suggests that these miRNAs may be potential biomarkers for CRC diagnosis. To verify this point of view, miRNASeq data samples for COAD stored in TCGA were adopted. Adenocarcinoma of the colon is the most common histopathological type of CRC, here we will uniformly called it as CRC. The miRNASeq data of CRC that we used here were in batch 28 including 31 CRC data samples and 3 matched normal samples. Firstly, we picked up miRNAs sequence data that belong to the 21 miRNAs, 12 miRNAs were selected, thereinto, miR-630 was found to be zero in all the 34 CRC miRNASeq samples. Ignored the miR-630, 11 miRNAs were remained in the data samples. Then, hierarchical clustering analysis in Matlab was adopted on the 34 CRC miRNASeq samples (see Fig. 4). Results show that a panel of 11 miRNAs is sufficient to distinguish CRC patients from the healthy subjects. The expression profiles of 11 miRNAs respectively in normal colorectal and CRC samples were described in Fig. 5. In normal colorectal samples, the expression of miR-21 is lower than miR-192 and miR-22 and expression of miR-22 is slightly higher than that of miR-192. In CRC samples, miR-21 and miR-192 are approximately equivalent in the expression and far more than that of miR-22. Compared with normal colorectal samples, both the expressions of miR-21 and miR-192 are upregulated in CRC samples, but the miR-22 is downregulated.
By KEGG pathway tool24, we get the gene lists that evolved in different pathways. Thus, genes that presented in the overlapped four pathways respectively could be selected. Then from the miRNA-mRNA interaction reference given by database such as miRanda20, we further get target genes regulated by the 21 miRNAs respectively in the four overlapped pathways (Fig. 6). Among those genes, as can be seen from the Fig. 6, most of those genes evolved in hsa04350TGF-beta signaling pathway. Furthermore, Type I diabetes mellitus, Allograft rejection and Graft-versus-host disease are signaling pathways that correlated to immune response. The reasons for immune response are various. Depending on these immune response pathways, it is difficult to discriminate whether the correlated dysregulated miRNAs are directly related to the CRC or are a secondary response in the histologic progression of the cancer. Bring together these factors, TGF-beta signaling pathway was regarded as the most important pathway that related to the CRC.
From Fig. 3(b), 15 significantly differential repressed mRNAs were overlapped between the four samples. Next, we paid close attention to the TGF-beta signaling pathway to see the distribution of 15 significantly differential repressed mRNAs between the four samples (see Fig. 7). As can be seen from the diagram, there are nine genes evolved in all the four CRC samples. To study the potential biological function of the nine overlapped genes, we submit only the nine genes and see their distribution on the TGF-beta signaling pathway (see Fig. 8).
TGF-beta signaling pathway plays a unique and pivotal role in homeostasis, wound healing, carcinogenesis, fibrosis, angiogenesis and differentiation of the cell25,26. TGF-beta and its signaling effectors influence cancer biological behaviors. The TGF-beta signaling pathway was proved to be a double-edged sword in cancer that plays as both a tumor suppressor and a cancer promoter27. From the enriched genes in TGF-beta signaling pathway, we can see that genes Smad6/7, which are located in downstream of TNF-alpha, play as an inhibitory factor to Smad2/3. By the activated TGF-βRI receptor, Smad2/3 are phosphorylated at the carboxyl terminal serines and form heteromeric complexes with Smad4. Ultimately, Smad2/3/4 complex translocates into the nucleus and binds to specific regulatory elements on target genes28,29. Smad 2/3/4 complex once in the nucleus, induces among others, a cyclin-dependent kinase (CDK) inhibitor p21, which will lead to growth arrest30. Protein p21 is the product of waf/cip1 gene, an inhibitor of CDK, and is a powerful and reversible inhibitor of the propagation of cell cycle at G1 and G2 activated upon DNA damage. The protein p21 interacts with complexes of CDK2 and cyclin A or cyclin E and thereby inhibits the activity of CDK2, preventing progression of cell cycle31.
Indeed, we find that miR-21 has a significantly differential repressed effect on the Smad7 gene and miR-21 is up-regulated in all the four CRC samples respectively (Table in supplementary). In addition, Smad7 has been identified as a target gene of miR-21 namely in fibrotic lung diseases and diabetic nephropathy32,33. The human miR-21 gene is located on chromosome 17q23-1 overlapping with the TMEM49 gene, a human homologue of rat Vacuole Membrane Protein 1 (VMP1)34. There have been several studies indicated that miR-21 expression was significantly higher in CRC compared with the adjacent normal tissues35,36,37,38,39. Li et al. demonstrate that miR-21 and Smad7 are critical regulators of TGF-β1 signaling during the induction of carcinoma associated fibroblasts(CAF) formation40. They find that the overexpression of Smad7 or the depletion of miR-21 blocks TGF-β1-induced CAF formation, whereas the overexpression of miR-21 or the depletion of Smad7 promotes CAF formation, even without TGF-β1 stimulation. Carcinoma associated fibroblasts are activated fibroblasts and a key cellular component of tumor stroma. Through specific communication with cancer cells, CAFs not only directly promote tumor progression41,42 and metastasis43,44, but are also involved in the initiation of cancer45,46,47. Several studies have reported that the infection of pre-miR-21 lentiviral vector in CRC cell lines including HT-29, Colo206f, LIM 1863, SW480 and DLD1 cells can induce significant cell proliferation, enhance migratory and invasive properties, and decrease apoptosis. In contrast, knockdown of miR-21 could significantly decrease cell proliferation, suppress the invasion, migration and increase the apoptosis48,49,50. Sprouty2 (Spry2) was considered as a tumor suppressor gene in cancer cells. The expression of Spry2 will inhibit the growth of HCT-116 cells, promote apoptosis and induce sensitization to 5-fluorouracil and metformin. But the knockdown of miR-21 in HCT-116 cells correlated with the elevated expression of Spry2, and the proliferation rate of HCT-116 was down-regulated, indicating that function of Spry2 in CRC is regulated by miR-2151.
Validation on wet experiments
It inspirited us that MiR-21 may be regarded as a target for inhibition the outgrowth of CRCs according the above data analysis. To verify this point, some wet experiments were carried out. Three CRC tissue samples and their corresponding paraneoplastic healthy tissue samples were adopted in this section. To dissect the expression difference of miR-21 between CRCs and healthy samples, qPCR analysis was done on the three groups of samples. Results show that the expression level of miR-21 are higher in all cancer samples than that in control groups with fold changes 1.466, 2.118 and 2.471 respectively (see Fig. 9). These results are consistent with the conclusion obtained from above studies and indicates miR-21 could be regarded as a target in CRC treatment.
As described in Fig. 8, differentially repressed Smad6/7 locate in an important position which is correlated to both the cell cycle and embryo differentiation. Smad7 has been validated to be the target gene of miR-21 in previously experiments32,33 and was regard as a pivot factor in cancer. Interestingly, though both Smad6 and Smad7 are the targets of miR21, there is lack of reports that miR-21 could regulate Smad6 in colon cancer cells, to the best of our knowledge. To examine the Smad6 expression level treated with and without inhibition of miR-21, PCR analysis were implemented. As our expected, results show that the expression level of Smad6 is becoming significantly higher when inhibit the level of miR-21 in colon cancer cells (see Fig. 10).
Finally, to examine the effect of miR-21 on colon cancer cell growth, miR-21 antisense was inducted into the cells, the cell cycle analysis was performed. As our expect, the growth of CRCs was significantly inhibited as shown in Fig. 11. These data suggest miR-21 inhibition in CRCs could effectively impair the growth of tumor cells and thus provide a therapeutic target for CRC treatment.
Real Time Quantitative Polymerase Chain Reaction (qRT-PCR)
Total RNA of CRC tissue samples and their corresponding paraneoplastic healthy tissue samples were extracted using Trizol reagent according to the supplier’s instruction (Invitrogen, USA) and quantified by spectrophotometry at 260 nm. Reverse transcription was performed for 60 min at 42 °C, followed by 5 min at 85 °C to inactivate the reverse transcriptase. MicroRNA expression level was examined in all samples. The approach of the experiment followed standard protocols, qRT-PCR was performed on the Applied Biosystems 7500 Sequence Detection System (BD, Michigan, USA). The reactions were amplified over 40 cycles of 95 °C for 15s and 60 °C for 1 min. Afterwards, a thermal denaturation protocol was performed to determine the number of products present in each reaction. The reactions were typically run in triplicate. The cycle number at which the reaction crossed an arbitrarily placed threshold (Ct) was determined for each gene. Target gene expression was normalized to the expression of U6 in each sample. Data was analyzed using the method52.
Conclusions
Due to the stability of miRNAs during analysis and the development of sequencing methods, miRNA expression profiling was identified as a reliable method for investigation of mRNAs, proteins and pathways involved in particular biological processes. In this study, we comprehensively analyze a series of CRC miRNAs expression profiles data, 21 miRNAs that have significantly differential repressed effect on target genes were found. Gene function analysis show that TGF-beta signaling pathway may involved in colorectal carcinogenesis and miR-21 was found to be important in this process. Inhibition miR-21 could hinder the growth of CRC growth. Thus, through miRNA sequencing analyzing, we could characterize the CRC with a panel of 21 miRNAs, as well as select potential target for CRC treatment.
Additional Information
How to cite this article: Xu, P. et al. Colorectal cancer characterization and therapeutic target prediction based on microRNA expression profile. Sci. Rep. 6, 20616; doi: 10.1038/srep20616 (2016).
References
Edwards, B. K. et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120, 1290–1314, doi: 10.1002/cncr.28509 (2014).
Torre, L. A. et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians 65, 87–108, doi: 10.3322/caac.21262 (2015).
Siegel, R. et al. Cancer treatment and survivorship statistics, 2012. CA: a cancer journal for clinicians 62, 220–241, doi: 10.3322/caac.21149 (2012).
Wienholds, E. & Plasterk, R. H. MicroRNA function in animal development. FEBS Lett 579, 5911–5922, doi: 10.1016/j.febslet.2005.07.070 (2005).
Esteller, M. Non-coding RNAs in human disease. Nat Rev Genet 12, 861–874, doi: 10.1038/nrg3074 (2011).
Kanellopoulou, C. & Monticelli, S. A role for microRNAs in the development of the immune system and in the pathogenesis of cancer. Seminars in cancer biology 18, 79–88, doi: 10.1016/j.semcancer.2008.01.002 (2008).
Lovat, F., Valeri, N. & Croce, C. M. MicroRNAs in the pathogenesis of cancer. Seminars in oncology 38, 724–733, doi: 10.1053/j.seminoncol.2011.08.006 (2011).
Gotte, M. MicroRNAs in breast cancer pathogenesis. Minerva ginecologica 62, 559–571 (2010).
Dela Cruz, F. & Matushansky, I. MicroRNAs in chromosomal translocation-associated solid tumors: learning from sarcomas. Discovery medicine 12, 307–317 (2011).
Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).
Iorio, M. V. & Croce, C. M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO molecular medicine 4, 143–159, doi: 10.1002/emmm.201100209 (2012).
An, J., Zhu, X., Wang, H. & Jin, X. A dynamic interplay between alternative polyadenylation and microRNA regulation: implications for cancer (Review). Int J Oncol 43, 995–1001, doi: 10.3892/ijo.2013.2047 (2013).
Zeng, W. et al. Predictive power of circulating miRNAs in detecting colorectal cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 36, 2559–2567, doi: 10.1007/s13277-014-2872-2 (2015).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102, 15545–15550, doi: 10.1073/pnas.0506580102 (2005).
Li, X., Shen, L., Shang, X. & Liu, W. Subpathway Analysis based on Signaling-Pathway Impact Analysis of Signaling Pathway. PloS one 10, e0132813, doi: 10.1371/journal.pone.0132813 (2015).
Vrahatis, A. G., Dimitrakopoulou, K., Balomenos, P., Tsakalidis, A. K. & Bezerianos, A. CHRONOS: A time-varying method for microRNA-mediated sub-pathway enrichment analysis. Bioinformatics, doi: 10.1093/bioinformatics/btv673 (2015).
Sun, B., Yang, F., Hu, F.-H., Huang, N.-P. & Xiao, Z.-D. Comprehensive annotation of microRNA expression profiles. BMC genetics 14, 120 (2013).
Nishida, N. et al. Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters. Clin. Cancer Res. 18, 3054–3070, doi: 10.1158/1078-0432.ccr-11-1078 (2012).
Wagner, G. P., Kin, K. & Lynch, V. J. Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory in Biosciences 131, 281–285, doi: 10.1007/s12064-012-0162-3 (2012).
Betel, D., Koppal, A., Agius, P., Sander, C. & Leslie, C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome biology 11, R90, doi: 10.1186/gb-2010-11-8-r90 (2010).
Ulitsky, I., Laurent, L. C. & Shamir, R. Towards computational prediction of microRNA function and activity. Nucleic acids research 38, doi: 10.1093/nar/gkq570 (2010).
Friedman, R. C., Farh, K. K. H., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Research 19, 92–105 (2009).
Sahoo, S. & Albrecht, A. A. Ranking of microRNA target prediction scores by Pareto front analysis. Comput Biol Chem 34, 284–292, doi: 10.1016/j.compbiolchem.2010.09.005 (2010).
Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research 28, 27–30 (2000).
Derynck, R. & Feng, X. H. TGF-beta receptor signaling. Biochimica et biophysica acta 1333, F105–150 (1997).
Massague, J. TGF-beta signal transduction. Annual review of biochemistry 67, 753–791, doi: 10.1146/annurev.biochem.67.1.753 (1998).
Akhurst, R. J. & Derynck, R. TGF-beta signaling in cancer-a double-edged sword. Trends in cell biology 11, S44–51 (2001).
Miyazono, K., ten Dijke, P. & Heldin, C. H. TGF-beta signaling by Smad proteins. Advances in immunology 75, 115–157 (2000).
Derynck, R., Zhang, Y. & Feng, X. H. Smads: transcriptional activators of TGF-beta responses. Cell 95, 737–740 (1998).
Lampropoulos, P. et al. TGF-beta signalling in colon carcinogenesis. Cancer letters 314, 1–7, doi: 10.1016/j.canlet.2011.09.041 (2012).
Reynisdottir, I., Polyak, K., Iavarone, A. & Massague, J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes & development 9, 1831–1845 (1995).
Liu, G. et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. The Journal of experimental medicine 207, 1589–1597, doi: 10.1084/jem.20100035 (2010).
Zhong, X. et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 56, 663–674, doi: 10.1007/s00125-012-2804-x (2013).
Zhao, J., Xu, G., Zhang, Y. & Zhao, G. Emerging role of microRNA-21 in colorectal cancer. Cancer biomarkers : section A of Disease markers, doi: 10.3233/CBM-150468 (2015).
Monzo, M. et al. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res 18, 823–833, doi: 10.1038/cr.2008.81 (2008).
Kulda, V. et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer genetics and cytogenetics 200, 154–160, doi: 10.1016/j.cancergencyto.2010.04.015 (2010).
Schee, K., Boye, K., Abrahamsen, T. W., Fodstad, O. & Flatmark, K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12, 505, doi: 10.1186/1471-2407-12-505 (2012).
Kanaan, Z. et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Annals of surgery 256, 544–551, doi: 10.1097/SLA.0b013e318265bd6f (2012).
Link, A. et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 19, 1766–1774, doi: 10.1158/1055-9965.EPI-10-0027 (2010).
Li, Q. et al. MiR-21/Smad 7 signaling determines TGF-beta1-induced CAF formation. Scientific Reports 3, 2038, doi: 10.1038/srep02038 (2013).
Dimanche-Boitrel, M. T. et al. In vivo and in vitro invasiveness of a rat colon-cancer cell line maintaining E-cadherin expression: an enhancing role of tumor-associated myofibroblasts. International journal of cancer. Journal international du cancer 56, 512–521 (1994).
Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348, doi: 10.1016/j.cell.2005.02.034 (2005).
Grum-Schwensen, B. et al. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer research 65, 3772–3780, doi: 10.1158/0008-5472.CAN-04-4510 (2005).
Olaso, E. et al. Tumor-dependent activation of rodent hepatic stellate cells during experimental melanoma metastasis. Hepatology 26, 634–642, doi: 10.1002/hep.510260315 (1997).
Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer research 59, 5002–5011 (1999).
Bhowmick, N. A. et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848–851, doi: 10.1126/science.1090922 (2004).
Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proceedings of the National Academy of Sciences of the United States of America 101, 4966–4971, doi: 10.1073/pnas.0401064101 (2004).
Cottonham, C. L., Kaneko, S. & Xu, L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. The Journal of biological chemistry 285, 35293–35302, doi: 10.1074/jbc.M110.160069 (2010).
Deng, J. et al. Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro . Biochemical and biophysical research communications 443, 789–795, doi: 10.1016/j.bbrc.2013.11.064 (2014).
Asangani, I. A. et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27, 2128–2136, doi: 10.1038/sj.onc.1210856 (2008).
Tsao, C.-J. microRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. International journal of molecular medicine, doi: 10.3892/ijmm.2012.910 (2012).
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25, 402–408 (2001).
Ng, E. K. et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375–1381, doi: 10.1136/gut.2008.167817 (2009).
Sarver, A. L. et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9, 401, doi: 10.1186/1471-2407-9-401 (2009).
Della Vittoria Scarpati, G. et al. Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. Biomed Res Int 2014, 840921, doi: 10.1155/2014/840921 (2014).
Chu, D. et al. MicroRNA-630 is a prognostic marker for patients with colorectal cancer. Tumor Biol. 35, 9787–9792, doi: 10.1007/s13277-014-2223-3 (2014).
Earle, J. S. et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. The Journal of molecular diagnostics : JMD 12, 433–440, doi: 10.2353/jmoldx.2010.090154 (2010).
Diosdado, B. et al. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. British journal of cancer 101, 707–714, doi: 10.1038/sj.bjc.6605037 (2009).
Arndt, G. M. et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9, 374, doi: 10.1186/1471-2407-9-374 (2009).
Kurokawa, K. et al. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. Journal of gastroenterology 47, 883–895, doi: 10.1007/s00535-012-0547-6 (2012).
Tsuchiya, N. et al. Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer research 71, 4628–4639, doi: 10.1158/0008-5472.CAN-10-2475 (2011).
Schepeler, T. et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer research 68, 6416–6424, doi: 10.1158/0008-5472.CAN-07-6110 (2008).
Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America 103, 2257–2261, doi: 10.1073/pnas.0510565103 (2006).
Huang, Z. H. et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. International Journal of Cancer 127, 118–126 (2010).
Chen, X. et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28, 1385–1392, doi: 10.1038/onc.2008.474 (2009).
Slattery, M. L. et al. MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes, chromosomes & cancer 50, 196–206, doi: 10.1002/gcc.20844 (2011).
Wang, Y. X. et al. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. Journal of digestive diseases 11, 50–54, doi: 10.1111/j.1751-2980.2009.00413.x (2010).
Acknowledgements
This work was supported by grants from the Natural Science Foundation of Jiangsu Province(No. BK2012122), the National Natural Science Foundation of China (NSFC) (No. 61071047), the Major State Basic Research Development Program of China (973 Program) (No. 2013CB932902), and the Specialized Research Fund for the Doctoral Program of Higher Education of China (No. 20130092110030). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author information
Authors and Affiliations
Contributions
Conceived and designed the experiments: B.S. and Z.D.X. Developed and implemented the analysis tools: P.X.; Performed the biological experiments: Y.L.Z. Analyzed the data: P.X., B.S. and Z.D.X. Wrote the paper: P.X., B.S. and Z.D.X. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Xu, P., Zhu, Y., Sun, B. et al. Colorectal cancer characterization and therapeutic target prediction based on microRNA expression profile. Sci Rep 6, 20616 (2016). https://doi.org/10.1038/srep20616
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep20616
This article is cited by
-
FoPA: identifying perturbed signaling pathways in clinical conditions using formal methods
BMC Bioinformatics (2019)
-
Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review
Endocrine (2019)
-
Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer
Journal of Hematology & Oncology (2017)
-
miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1
Molecular Cancer (2017)
-
MiR-218 Induces Neuronal Differentiation of ASCs in a Temporally Sequential Manner with Fibroblast Growth Factor by Regulation of the Wnt Signaling Pathway
Scientific Reports (2017)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.